Top Markets
Coin of the day
Faes Farma, S.A. Faes Farma, S.A.

Faes Farma, S.A.

FAE
株式のランク #7176
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research,... Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
株価
$5.42
最終同期: 2026-08-27
時価総額
$1.69B
変化(1日)
0.55%
変化(1年)
10.03%
ES
取引 Faes Farma, S.A. (FAE)

カテゴリー

Faes Farma, S.A.(FAE)の株式分割履歴
Faes Farma, S.A.株(シンボル:FAE)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 28, 2026に行われました。
Aug 28, 2026より前に購入されたFAE株は、現在0FAE株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割